Bausch Health Companies Inc. (NYSE:BHC) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its stake in Bausch Health Companies Inc. (NYSE:BHCFree Report) by 1.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,599,131 shares of the company’s stock after acquiring an additional 111,363 shares during the quarter. Vanguard Group Inc. owned about 3.17% of Bausch Health Companies worth $93,025,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of BHC. Principal Securities Inc. acquired a new stake in Bausch Health Companies during the fourth quarter worth about $31,000. Tower Research Capital LLC TRC increased its holdings in shares of Bausch Health Companies by 283.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,918 shares of the company’s stock worth $55,000 after buying an additional 5,112 shares during the last quarter. Bfsg LLC purchased a new stake in shares of Bausch Health Companies during the 4th quarter valued at approximately $63,000. Citigroup Inc. lifted its holdings in Bausch Health Companies by 73.3% in the third quarter. Citigroup Inc. now owns 20,820 shares of the company’s stock valued at $172,000 after acquiring an additional 8,804 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new position in Bausch Health Companies in the fourth quarter worth approximately $185,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BHC. Royal Bank of Canada decreased their price target on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a research note on Tuesday, April 23rd. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Wednesday, May 15th. Finally, Piper Sandler boosted their price target on shares of Bausch Health Companies from $7.00 to $9.00 and gave the company a “neutral” rating in a research note on Monday, April 29th.

Read Our Latest Stock Analysis on BHC

Bausch Health Companies Stock Performance

Shares of BHC opened at $7.23 on Monday. The company’s 50-day simple moving average is $6.85 and its 200-day simple moving average is $8.09. Bausch Health Companies Inc. has a 1 year low of $6.05 and a 1 year high of $11.46. The stock has a market capitalization of $2.61 billion, a PE ratio of -5.83 and a beta of 0.77.

Bausch Health Companies (NYSE:BHCGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.16). The company had revenue of $2.15 billion for the quarter, compared to analysts’ expectations of $2.18 billion. Bausch Health Companies had a negative return on equity of 2,370.91% and a negative net margin of 5.07%. On average, sell-side analysts predict that Bausch Health Companies Inc. will post 3.63 earnings per share for the current year.

Bausch Health Companies Profile

(Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

Read More

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHCFree Report).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.